191 related articles for article (PubMed ID: 37717224)
1. Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data.
De Greef A; Thirion R; Ghislain PD; Baeck M
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2869-2877. PubMed ID: 37717224
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
Kwon O; Senna MM; Sinclair R; Ito T; Dutronc Y; Lin CY; Yu G; Chiasserini C; McCollam J; Wu WS; King B
Am J Clin Dermatol; 2023 May; 24(3):443-451. PubMed ID: 36855020
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2.
Senna M; Mostaghimi A; Ohyama M; Sinclair R; Dutronc Y; Wu WS; Yu G; Chiasserini C; Somani N; Holzwarth K; King B
J Eur Acad Dermatol Venereol; 2024 Mar; 38(3):583-593. PubMed ID: 38391212
[TBL] [Abstract][Full Text] [Related]
4. Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review.
Egeberg A; Linsell L; Johansson E; Durand F; Yu G; Vañó-Galván S
Dermatol Ther (Heidelb); 2023 Dec; 13(12):2951-2991. PubMed ID: 37833617
[TBL] [Abstract][Full Text] [Related]
5. A Review of JAK Inhibitors for Treatment of Alopecia Areata in the Military Health Care System.
Song CJ; Riley CA; Wilkison BD; Cho S
Mil Med; 2024 Jun; ():. PubMed ID: 38850223
[TBL] [Abstract][Full Text] [Related]
6. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials.
King B; Shapiro J; Ohyama M; Egeberg A; Piraccini BM; Craiglow B; Sinclair R; Chen YF; Wu WS; Ding Y; Somani N; Dutronc Y
Br J Dermatol; 2023 Nov; 189(6):666-673. PubMed ID: 37708254
[TBL] [Abstract][Full Text] [Related]
7. Baricitinib: A Review in Severe Alopecia Areata.
Fung S; Shirley M
Am J Clin Dermatol; 2023 Jul; 24(4):661-668. PubMed ID: 37326792
[TBL] [Abstract][Full Text] [Related]
8. Two Phase 3 Trials of Baricitinib for Alopecia Areata.
King B; Ohyama M; Kwon O; Zlotogorski A; Ko J; Mesinkovska NA; Hordinsky M; Dutronc Y; Wu WS; McCollam J; Chiasserini C; Yu G; Stanley S; Holzwarth K; DeLozier AM; Sinclair R;
N Engl J Med; 2022 May; 386(18):1687-1699. PubMed ID: 35334197
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials.
Ko JM; Mayo TT; Bergfeld WF; Dutronc Y; Yu G; Ball SG; Somani N; Craiglow BG
JAMA Dermatol; 2023 Sep; 159(9):970-976. PubMed ID: 37556146
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.
King B; Ko J; Forman S; Ohyama M; Mesinkovska N; Yu G; McCollam J; Gamalo M; Janes J; Edson-Heredia E; Holzwarth K; Dutronc Y
J Am Acad Dermatol; 2021 Oct; 85(4):847-853. PubMed ID: 34090959
[TBL] [Abstract][Full Text] [Related]
11. Baricitinib as the first systemic treatment for severe alopecia areata.
Kincaid CM; Arnold JD; Mesinkovska NA
Expert Rev Clin Immunol; 2023 Jun; 19(6):565-573. PubMed ID: 37042112
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of baricitinib in patients with moderate-to-severe refractory alopecia areata in real world: An open-label, single-center study.
Bi L; Wang C; Du Y; Su T; Zhao M; Lin X; Fan W; Sun W
J Cosmet Dermatol; 2024 Apr; 23(4):1417-1421. PubMed ID: 38116864
[TBL] [Abstract][Full Text] [Related]
13. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
Almutairi N; Nour TM; Hussain NH
Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2.
Taylor S; Korman NJ; Tsai TF; Shimomura Y; Feely M; Dutronc Y; Wu WS; Somani N; Tosti A
Dermatol Ther (Heidelb); 2023 Dec; 13(12):3181-3191. PubMed ID: 37740856
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis.
Wei D; Chen Y; Shen Y; Xie B; Song X
Front Immunol; 2023; 14():1152513. PubMed ID: 37138884
[TBL] [Abstract][Full Text] [Related]
16. Review of Baricitinib in the Treatment of Alopecia Areata.
Singh R; Driscoll MS
J Drugs Dermatol; 2023 Sep; 22(9):935-940. PubMed ID: 37683061
[TBL] [Abstract][Full Text] [Related]
17. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials.
King B; Mostaghimi A; Shimomura Y; Zlotogorski A; Choi GS; Blume-Peytavi U; Passeron T; Holzwarth K; Dutronc Y; McCollam J; Yang FE; Stanley S; Wu WS; Sinclair R
Br J Dermatol; 2023 Feb; 188(2):218-227. PubMed ID: 36763878
[TBL] [Abstract][Full Text] [Related]
18. Treatment of moderate-to-severe alopecia areata in patients over the age of 65 with baricitinib.
Tang GT; Triwongwaranat D; Sinclair R; Joseph S; Eisman S; Rathnayake D; Varathan V; Trindade de Carvalho L; Bhoyrul B
Clin Exp Dermatol; 2024 Jan; ():. PubMed ID: 38270233
[TBL] [Abstract][Full Text] [Related]
19. Exploring Janus kinase inhibitors for alopecia areata: a comprehensive review.
Bushwereb R; Srivastava G
Ital J Dermatol Venerol; 2024 May; ():. PubMed ID: 38780910
[TBL] [Abstract][Full Text] [Related]
20. Baricitinib for the Treatment of Alopecia Areata.
Freitas E; Guttman-Yassky E; Torres T
Drugs; 2023 Jun; 83(9):761-770. PubMed ID: 37195491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]